CDEK by Data4ThePeople

Search by Name FDA Approval Trends Advanced Search FDA Approved Drugs

Search by Name Organization Trends Advanced Search

Indications Mechanisms Trials FDA Approvals

About CDEK Glossary Advanced Search Guide Search by Name

Drugs

Search by Name FDA Approval Trends Advanced Search FDA Approved Drugs

Organizations

Search by Name Organization Trends Advanced Search

Indications Mechanisms Trials FDA Approvals

About

About CDEK Glossary Advanced Search Guide Search by Name

← All indications

Myeloma Proteins

Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA.

Drugs by status

Phase 3 trials (4)

urea
doxorubicin
vincristine
daunorubicin

CDEK

The Clinical Drug Experience Knowledgebase — tracking drugs, sponsoring organizations, and clinical trials from first-in-human testing through approval.

Browse

Drugs
Organizations
Trials

About

About CDEK
Glossary

Built and maintained by Data4ThePeople.

YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED "AS IS", WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.